Insitro vs Opentrons
Side-by-side comparison of AI visibility scores, market position, and capabilities
Drug discovery company founded by Daphne Koller integrating ML with high-throughput biology; raised $400M+ to build proprietary biological datasets for predicting drug targets and clinical outcomes in neurology, metabolic, and oncology programs.
About
Insitro is a drug discovery company founded in 2018 by Daphne Koller, a pioneer in machine learning and computational biology, having raised over $400M to build an integrated ML and biology platform. The company generates large-scale biological datasets using automated laboratory systems and human induced pluripotent stem cell models of disease, then trains machine learning models on this data to predict drug targets, patient stratification, and clinical outcomes. Unlike companies that apply ML to existing datasets, Insitro builds proprietary biological datasets specifically designed to train predictive models for drug discovery. The platform is being applied to neurological diseases, metabolic disorders, and oncology with the goal of identifying drug candidates more likely to succeed in clinical trials. Insitro has established partnerships with major pharmaceutical companies including Gilead Sciences and Bristol Myers Squibb to co-develop drugs using the platform. The company represents a model for how ML can be deeply integrated into pharmaceutical R&D rather than applied as a surface-level analytical layer.
Opentrons democratizes lab automation with 10,000+ OT-2 and Flex robotic systems deployed globally; raised $200M+ including $20M Series C in Nov 2025; partnered with BD and HighRes for AI agent-to-agent workflows.
About
Opentrons Labworks is a New York-based life sciences company that designs and manufactures affordable, open-source liquid-handling robots for research laboratories. Founded in 2014, Opentrons'' mission is to democratize biology by making advanced lab automation accessible to life scientists at any institution — from academic labs with limited budgets to leading pharmaceutical companies. Its flagship products, the OT-2 and the newer Opentrons Flex, are programmable robotic platforms that automate repetitive liquid-handling tasks such as PCR setup, nucleic acid extraction, ELISA assays, and next-generation sequencing sample preparation.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.